Inactive Instrument

Actavis PLC Nyse

IE00BD1NQJ95

Pharmaceuticals

End-of-day quote Nyse Other stock markets
- ^USD	-

Mar. 05	Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	CI
2023	Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	CI

Actavis : Pfizer approaches Actavis to gauge interest in deal - Bloomberg

September 23, 2014 at 07:24 pm EDT

(Reuters) - Pfizer Inc has approached Dublin-based generic drugmaker Actavis Plc to express its interest in an acquisition, Bloomberg reported, citing people with knowledge of the matter.

The companies are not currently in formal talks and Pfizer has not made an offer, the Bloomberg report said.

Pfizer in May abandoned its attempt to buy British drugmaker AstraZeneca Plc for nearly 70 billion pounds.

Actavis, which has a market capitalization of about $63 billion (38.4 billion pounds), obtained an Irish tax domicile by acquiring Warner Chilcott Plc last year.

Tough new U.S. rules on corporate "inversions" on Tuesday sent a chill through the market for the tax-avoidance deals, both pending and potential.

(Reporting by Ankur Banerjee in Bangalore; Editing by Sriraj Kalluvila)

Stocks treated in this article : Pfizer Inc., AstraZeneca plc, Actavis PLC

Latest news about Actavis PLC

Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21	Mar. 05	CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence	23-09-18	CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)	23-08-30	CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®	23-05-15	CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc	23-01-18	CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection	23-01-17	CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting	22-10-07	CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body	22-08-31	CI
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition	22-08-03	CI
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics	22-06-13	CI
PatientFi Expands Partnership with Allergan Aesthetics	22-04-06	CI
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.	21-12-15	CI
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting	21-11-19	CI
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia	21-10-26	CI
Allergan plc entered into a definitive agreement to acquire Soliton, Inc. for approximately $510 million.	21-05-09	CI
Allergan Aesthetics Launches SkinMedica® Neck Correct Cream	21-04-01	CI
GLOBAL MARKETS LIVE: Alibaba, Nokia, Berkshire Hathaway…	21-03-16
Allergan Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia	21-02-25	CI
PatientFi® Enters into Co-Marketing Agreement with Allergan Aesthetics	21-02-08	CI
Allergan Aesthetics Enters into Option to Acquire Cypris Medical	21-01-12	CI
Street Color: Allergan Reportedly Wins US Import Ban on Jeuveau for 21 Months, Bloomberg Says	20-12-16	MT
Allergan Aesthetics entered into an agreement to acquire Dermal Filler business from Luminera Derm Ltd. for approximately $210 million.	20-10-06	CI
SkinMedica® Launches TNS® Advanced+ Pro-Infusion Serum for DiamondGlow™	20-09-30	CI
Stemson Therapeutics announced that it has received $7.5 million in funding from Allergan plc, Fortunis Capital Limited	20-09-15	CI
Allergan Aesthetics, Abbvie and Skinbetter Science Announce Launch of New Long-Term, Educational Initiative – Dream	20-09-14	CI

Allergan plc is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.61%	672B
NOVO NORDISK A/S	+25.87%	570B
JOHNSON & JOHNSON	-5.24%	360B
MERCK & CO., INC.	+16.49%	321B
ABBVIE INC.	+8.28%	300B
ASTRAZENECA PLC	+7.09%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Actavis PLC Nyse

Equities

IE00BD1NQJ95

Pharmaceuticals

Actavis : Pfizer approaches Actavis to gauge interest in deal - Bloomberg

Latest news about Actavis PLC

Chart Actavis PLC

Company Profile

Sector Other Pharmaceuticals